
[EPISODE 25] Adam Stasio Talks, Large Data Sets, Breaking Down Problems, and Tech-Driven Solutions
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
BioAgilytix Commits to United Nations Global Compact Leading bioanalytical services provider pledges to act in support of human rights
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
BioAgilytix Commits to United Nations Global Compact Leading bioanalytical services provider pledges to act in support of human rights
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
Antibody drug conjugates (ADCs) continue to show significant therapeutic promise, and BioAgilytix is here to help support their development for life-changing outcomes. We have been supporting customers at the leading edge with expert antibody drug conjugate testing services, and will apply that first-hand expertise to your distinct project requirements.
ADC development work specialized and technically challenging, combining both chemistry and biotechnology innovations. The heterogeneous mixture of monoclonal antibody and small molecule payload requires studies that characterize the clinical pharmacology of both antibody-drug conjugate components. Minimal regulatory parameters have been formalized around this emerging science, also creating challenges. Because of this complexity, your partner in the development of antibody drug conjugates must be well-versed in conjugation strategies, and understand the critical factors that should be considered to select the appropriate bioanalytical techniques.
BioAgilytix’s scientific team has been supporting customers at the leading edge of antibody drug conjugate development, and will apply that first-hand expertise to your distinct project requirements. Our scientists understand the complexity of ADCs and the development of assays required to measure free total drug conjugates and naked molecules for PK analysis. In fact, we have supported immunogenicity and PK studies for antibody drug conjugates in a variety of species including rodents, humans, and nonhuman primates.
BioAgilytix provides ligand binding and LC/MS assay development and validation on multiple platforms in support of antibody-drug conjugate projects. BioAgilytix has experience developing assays for immunogenicity across the bioanalytical lifecycle requiring high drug tolerance levels. Our state-of-the-art bioanalytical laboratory also allows for development and analysis of potency assays, as well as bioanalytical testing of antibody-drug conjugates, using the variety of bioanalytical platforms listed below.
BioAgilytix has become the partner of choice for organizations seeking to advance their biologics strategy, and take the lead in developing next-generation antibody drug conjugates for more targeted and effective therapeutic treatments.
Our experts understand the complexities that must be addressed in immunogenicity studies, PK analysis, and NAb assays related to ADCs, and will help you determine the optimal analytical equipment platform to yield high-quality data results. We offer these services under GLP, GMP, and GCP to meet your regulatory requirements.
Let us help you remove the roadblocks of complexity on your path to developing safe, effective antibody drug conjugates.